Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.

BACKGROUND: At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiv...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Health Technol Assess
Main Authors: Melendez-Torres, G J, Auguste, Peter, Armoiry, Xavier, Maheswaran, Hendramoorthy, Court, Rachel, Madan, Jason, Kan, Alan, Lin, Stephanie, Counsell, Carl, Patterson, Jacoby, Rodrigues, Jeremy, Ciccarelli, Olga, Fraser, Hannah, Clarke, Aileen
Format: Artigo
Jezik:Inglês
Izdano: NIHR Journals Library 2017
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5623930/
https://ncbi.nlm.nih.gov/pubmed/28914229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta21520
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki